Perry A. Karsen

Perry A. Karsen has served as a director on our board of directors since January 2016, and was the chairman of our board of directors from April 2016 until June 2022. Mr. Karsen was the chief executive officer of the Celgene Cellular Therapeutics division of Celgene Corporation, or Celgene, from 2013 until his retirement in 2015. Mr. Karsen served as executive vice president and chief operations officer of Celgene from 2010 to 2013, and as senior vice president and head of worldwide business development of Celgene from 2004 to 2009. Mr. Karsen was chief executive officer of Pearl Therapeutics Inc., from 2009 to 2010. Earlier in his career, Mr. Karsen held executive positions at Human Genome Sciences, Inc., Bristol-Myers Squibb Co., Genentech, Inc. and Abbott Laboratories. He is a member of the boards of directors of publicly traded life sciences companies Intellia Therapeutics, Inc. where he serves as chairman of the board. Previously, he was executive chair of OncoMed Pharmaceuticals, Inc. (merged with MEREO Biopharma NASDAQ: MREO) and a director of Voyager Therapeutics, Inc. Mr. Karsen received a Masters of Management from Northwestern University’s Kellogg Graduate School of Management, a Masters of Arts in Teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign.